Humacyte Statistics
Total Valuation
Humacyte has a market cap or net worth of $163.90 million. The enterprise value is $150.88 million.
| Market Cap | 163.90M |
| Enterprise Value | 150.88M |
Important Dates
The last earnings date was Wednesday, August 12, 2026, before market open.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Humacyte has 277.80 million shares outstanding. The number of shares has increased by 45.78% in one year.
| Current Share Class | 277.80M |
| Shares Outstanding | 277.80M |
| Shares Change (YoY) | +45.78% |
| Shares Change (QoQ) | +18.37% |
| Owned by Insiders (%) | 3.52% |
| Owned by Institutions (%) | 26.71% |
| Float | 251.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 77.28 |
| Forward PS | 22.31 |
| PB Ratio | 5.07 |
| P/TBV Ratio | 5.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 71.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.21, with a Debt / Equity ratio of 2.14.
| Current Ratio | 6.21 |
| Quick Ratio | 5.37 |
| Debt / Equity | 2.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.73 |
Financial Efficiency
Return on equity (ROE) is -547.87% and return on invested capital (ROIC) is -74.17%.
| Return on Equity (ROE) | -547.87% |
| Return on Assets (ROA) | -49.87% |
| Return on Invested Capital (ROIC) | -74.17% |
| Return on Capital Employed (ROCE) | -89.70% |
| Weighted Average Cost of Capital (WACC) | 16.19% |
| Revenue Per Employee | $11,527 |
| Profits Per Employee | -$525,370 |
| Employee Count | 184 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 9.03 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -61.91% in the last 52 weeks. The beta is 2.47, so Humacyte's price volatility has been higher than the market average.
| Beta (5Y) | 2.47 |
| 52-Week Price Change | -61.91% |
| 50-Day Moving Average | 0.67 |
| 200-Day Moving Average | 0.95 |
| Relative Strength Index (RSI) | 42.84 |
| Average Volume (20 Days) | 10,102,171 |
Short Selling Information
The latest short interest is 31.94 million, so 11.50% of the outstanding shares have been sold short.
| Short Interest | 31.94M |
| Short Previous Month | 31.49M |
| Short % of Shares Out | 11.50% |
| Short % of Float | 12.72% |
| Short Ratio (days to cover) | 4.70 |
Income Statement
In the last 12 months, Humacyte had revenue of $2.12 million and -$96.67 million in losses. Loss per share was -$0.50.
| Revenue | 2.12M |
| Gross Profit | -79.37M |
| Operating Income | -110.46M |
| Pretax Income | -96.74M |
| Net Income | -96.67M |
| EBITDA | -103.23M |
| EBIT | -110.46M |
| Loss Per Share | -$0.50 |
Balance Sheet
The company has $79.90 million in cash and $66.88 million in debt, with a net cash position of $13.02 million or $0.05 per share.
| Cash & Cash Equivalents | 79.90M |
| Total Debt | 66.88M |
| Net Cash | 13.02M |
| Net Cash Per Share | $0.05 |
| Equity (Book Value) | 31.26M |
| Book Value Per Share | 0.11 |
| Working Capital | 77.84M |
Cash Flow
In the last 12 months, operating cash flow was -$97.19 million and capital expenditures -$367,000, giving a free cash flow of -$97.56 million.
| Operating Cash Flow | -97.19M |
| Capital Expenditures | -367,000 |
| Depreciation & Amortization | 7.23M |
| Net Borrowing | 38.22M |
| Free Cash Flow | -97.56M |
| FCF Per Share | -$0.35 |
Margins
| Gross Margin | n/a |
| Operating Margin | -5,207.78% |
| Pretax Margin | -4,560.82% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Humacyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -45.78% |
| Shareholder Yield | -45.78% |
| Earnings Yield | -58.98% |
| FCF Yield | -59.52% |
Analyst Forecast
The average price target for Humacyte is $1.85, which is 213.56% higher than the current price. The consensus rating is "Buy".
| Price Target | $1.85 |
| Price Target Difference | 213.56% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 279.06% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Humacyte has an Altman Z-Score of -8.48 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.48 |
| Piotroski F-Score | 4 |